Speaking during the virtual European Conference of Interventional Oncology (ECIO; 4 November 2020, online), José Hugo Luz (Curry Cabral Hospital and Nova Medical School, Lisbon, Portugal) presented the results of the randomised, controlled BestFLR (Best future liver remnant) trial.
The test shows that portal vein embolization with Glubran 2 can promote greater liver growth than other embolic procedures.
